Details for Patent: 7,612,208
✉ Email this page to a colleague
Which drugs does patent 7,612,208 protect, and when does it expire?
Patent 7,612,208 protects LENVIMA and is included in one NDA.
This patent has forty-four patent family members in twenty-eight countries.
Summary for Patent: 7,612,208
Title: | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide or the solvate of the salt and a process for preparing the same |
Abstract: | A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof. |
Inventor(s): | Matsushima; Tomohiro (Tsukuba, JP), Nakamura; Taiju (Kamisu, JP), Yoshizawa; Kazuhiro (Kamisu, JP), Kamada; Atsushi (Tsukuba, JP), Ayata; Yusuke (Kamisu, JP), Suzuki; Naoko (Ushiku, JP), Arimoto; Itaru (Tokyo, JP), Sakaguchi; Takahisa (Tsukuba, JP), Gotoda; Masaharu (Tsukuba, JP) |
Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
Application Number: | 10/577,531 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Dosage form; |
Recent additions to Drugs Protected by US Patent 7,612,208
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE | 206947 | Feb 13, 2015 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,612,208
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,612,208
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2003-430939 | Dec 25, 2003 |
PCT Information | |||
PCT Filed | December 22, 2004 | PCT Application Number: | PCT/JP2004/019223 |
PCT Publication Date: | July 14, 2005 | PCT Publication Number: | WO2005/063713 |
International Family Members for US Patent 7,612,208
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2004309217 | ⤷ Try a Trial | |||
Brazil | PI0418200 | ⤷ Try a Trial | |||
Canada | 2543650 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |